Randomized Withdrawal Study in Patients With Schizophrenia
ConditionSchizophrenia
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVanda Pharmaceuticals
About this trial
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Eligibility criteria
Qualifiers
Males or females 18 to 65 years of age (inclusive)
Diagnosed with schizophrenia per DSM-5 criteria
In need of ongoing psychiatric treatment
Disqualifiers
DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
Trial design
Treatments tested in this trial
- iloperidone
- placebo
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov